Page 94 - Michael Erman News Today

Merck CEO Kenneth Frazier to retire at the end of June By Manas Mishra and Michael Erman Reuters NEW YORK (Reuters) - Merck & Co Inc said on Thursday Kenneth Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis. Frazier, 66, will not be handing over the reins completely, at least for now. He will remain with the drugmaker as executive chairman fo...

5 Min Read (Reuters) - Merck & Co Inc said on Thursday Ken Frazier, one of only a handful of Black executives leading major U.S. companies, will step down as chief executive officer at the end of June and be replaced by Chief Financial Officer Robert Davis. Frazier, 66, will remain with the drugmaker as executive chairman for a transition period. He had been due to retire in 2019, but the company scrapped a policy requiring its CEO to retire at age 65. Frazier was one of only five Black CEOs on...

U.S. health officials sought to speed up the sluggish pace of COVID-19 vaccinations on Thursday, as the coronavirus claimed over 4,000 American lives for a second straight day and employment data showed the pandemic further stifling the job market.

U.S. COVID Task Force says new cases on decline but variants pose threat 02/03/2021 17:09 WASHINGTON (Reuters) - New COVID-19 cases and hospitalizations appear to be on a downward trajectory in the United States as the Biden administration remains confident that it can hit its target of 100 million vaccines in 100 days, the White House Coronavirus Task Force said on Wednesday. However, Rachel Walensky, the director of the Centers for Disease Control and Prevention, warned that new COVID-19...

Updated Pfizer targets at least 2 billion COVID-19 vaccine doses this year, sees $15 billion in 2021 from the shots 3 Min Read (Reuters) - Pfizer Inc said on Tuesday it expects to generate $15 billion, or about a quarter of its total revenue this year, from sales of its COVID-19 vaccine co-developed with German partner BioNTech SE. Sales from the vaccine - on track to be the drugmaker’s top product this year - could top $15 billion if the company signs more supply contracts, it said. Pfizer ...

Pfizer expects $15 billion in 2021 sales from its COVID-19 vaccine By Manas Mishra and Michael Erman Reuters (Reuters) - Pfizer Inc said on Tuesday it expects to generate $15 billion, or about a quarter of its total revenue this year, from sales of its COVID-19 vaccine co-developed with German partner BioNTech SE. Sales from the vaccine - on track to be the drugmakers top product this year - could top $15 billion if the company signs more supply contracts, it said. The vaccine, which uses ...

Updated Pfizer targets at least 2 billion COVID-19 vaccine doses this year, sees $15 billion in 2021 from the shots 3 Min Read (Reuters) - Pfizer Inc said on Tuesday it expects to generate $15 billion, or about a quarter of its total revenue this year, from sales of its COVID-19 vaccine co-developed with German partner BioNTech SE. Sales from the vaccine - on track to be the drugmaker’s top product this year - could top $15 billion if the company signs more supply contracts, it said. Pfizer ...

Pfizer sees $15 billion in 2021 sales from COVID-19 vaccine 02/02/2021 14:10 (Reuters) -Pfizer Inc said on Tuesday it expected to generate $15 billion, or about a quarter of its total revenue this year, from the sale of its COVID-19 vaccine that it has developed with German partner BioNTech. The drugmaker is striving to deliver two billion doses of the vaccine in 2021 at a breakneck pace as countries rush to sign supply deals in an effort to control a pandemic that has killed over 2 million peo...

5 Min Read CHICAGO (Reuters) - Clinical trial data on two COVID-19 vaccines show that a coronavirus variant first identified in South Africa is lessening their ability to protect against the illness, underscoring the need to vaccinate vast numbers of people as quickly as possible, scientists said. FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed Novavax logo in this illustration taken, October 30, 2020. RE...

FILE PHOTO: Vials with a sticker reading, "COVID-19 / Coronavirus vaccine / Injection only" and a medical syringe are seen in front of a displayed Johnson & Johnson logo in this illustration taken October 31, 2020. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo (Reuters) - Johnson & Johnson said its single-dose vaccine was 72% effective in preventing COVID-19 in the United States but a lower rate of 66% was observed globally in the large trial conducted across three continents and ag...